Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease

NCT04691661 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease

Interventions

DRUG: Radotinib HCl 50 mg
DRUG: Placebo

Sponsor

Il-Yang Pharm. Co., Ltd.